Medincell
Medincell develops long-acting injectable treatments using its proprietary BEPO technology platform to improve patient adherence and therapeutic efficacy. The company focuses on therapeutic areas such as schizophrenia, with products like UZEDY already FDA-approved and others in late-stage clinical trials. Its business model involves internal R&D and collaborations with pharmaceutical companies and NGOs to provide accessible medicine globally.
Visit websiteJacou, France
Biotechnology
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €4.0M
- Funding rounds
- 2
Investors in Medincell
Investors on record for Medincell. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Medincell?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors